MX2014006662A - Direccionamiento de en2, pax2, y/o defb1 para tratamiento de afecciones de la próstata. - Google Patents

Direccionamiento de en2, pax2, y/o defb1 para tratamiento de afecciones de la próstata.

Info

Publication number
MX2014006662A
MX2014006662A MX2014006662A MX2014006662A MX2014006662A MX 2014006662 A MX2014006662 A MX 2014006662A MX 2014006662 A MX2014006662 A MX 2014006662A MX 2014006662 A MX2014006662 A MX 2014006662A MX 2014006662 A MX2014006662 A MX 2014006662A
Authority
MX
Mexico
Prior art keywords
pax2
defb1
targeting
treatment
agent
Prior art date
Application number
MX2014006662A
Other languages
English (en)
Inventor
Carlton D Donald
Original Assignee
Phigenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phigenix Inc filed Critical Phigenix Inc
Publication of MX2014006662A publication Critical patent/MX2014006662A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención actual se refiere a las composiciones y uso de las composiciones para tratar una afección de la próstata en un sujeto. El uso de la composición comprende administrar al sujeto una cantidad efectiva objetivo de una composición farmacéutica que tiene un primer agente que inhibe la expresión EN2 y/o actividad EN2 y un segundo agente que inhibe la expresión PAX2 y/o actividad PAX2. La composición farmacéutica puede comprender además un tercer agente que aumenta la expresión o actividad DEFB1.
MX2014006662A 2011-12-05 2011-12-05 Direccionamiento de en2, pax2, y/o defb1 para tratamiento de afecciones de la próstata. MX2014006662A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/063298 WO2013085483A1 (en) 2011-12-05 2011-12-05 Targeting en2, pax2, and/or defb1 for treatment of prostate conditions

Publications (1)

Publication Number Publication Date
MX2014006662A true MX2014006662A (es) 2015-04-16

Family

ID=48574704

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006662A MX2014006662A (es) 2011-12-05 2011-12-05 Direccionamiento de en2, pax2, y/o defb1 para tratamiento de afecciones de la próstata.

Country Status (6)

Country Link
US (1) US20140336130A1 (es)
JP (1) JP5990274B2 (es)
CN (1) CN104114189A (es)
IL (1) IL232965A0 (es)
MX (1) MX2014006662A (es)
WO (1) WO2013085483A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101698654B1 (ko) * 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
US11326210B2 (en) * 2015-01-30 2022-05-10 Glax Llc Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
CN106032532A (zh) * 2015-03-17 2016-10-19 中国医学科学院北京协和医院 一种小激活rna及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080081791A1 (en) * 2006-07-06 2008-04-03 Weida Huang Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi
GB0625321D0 (en) * 2006-12-19 2007-01-24 Univ Surrey Cancer biomarker
CN101970685B (zh) * 2007-01-16 2013-08-07 Musc研究发展基金会 诊断前列腺疾病的试剂盒

Also Published As

Publication number Publication date
US20140336130A1 (en) 2014-11-13
JP2015504858A (ja) 2015-02-16
IL232965A0 (en) 2014-07-31
CN104114189A (zh) 2014-10-22
WO2013085483A1 (en) 2013-06-13
JP5990274B2 (ja) 2016-09-07

Similar Documents

Publication Publication Date Title
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
SG178873A1 (en) Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
MY162903A (en) Methods of treatment of pancreatic cancer
MY166014A (en) Combination therapy methods for treating proliferative diseases
MX2019010601A (es) Terapia de combinacion para tratar cancer.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX369385B (es) Productos para cicatrizar heridas tisulares.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
EA201590880A1 (ru) Композиции и способы лечения протеинопатий
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
EP2490700A4 (en) EXTERNAL SKIN CARE COMPOSITION COMPRISING SALT AND SUGAR AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING VAGINOSIS AND USE THEREOF
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
TN2015000255A1 (fr) Chitine ou ses derives pour la prevention et/ou le traitement de parasitoses
PH12016501527A1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
BR112015004469A2 (pt) sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares
NZ754706A (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
MX2014006662A (es) Direccionamiento de en2, pax2, y/o defb1 para tratamiento de afecciones de la próstata.
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT